Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Sep 1:3:16.
doi: 10.1186/1755-1536-3-16.

The multifaceted role of pirfenidone and its novel targets

José Macías-Barragán  1 , Ana Sandoval-Rodríguez, Jose Navarro-Partida, Juan Armendáriz-Borunda
Affiliations

The multifaceted role of pirfenidone and its novel targets

José Macías-Barragán et al. Fibrogenesis Tissue Repair. .

Abstract

Background: Pirfenidone (PFD) is a molecule that exhibits antifibrotic properties in a variety of in vitro and animal models of lung, liver and renal fibrosis. These pathologies share many fibrogenic pathways with an abnormal fibrous wound-healing process; consequently, tissue repair and tissue regeneration-regulating mechanisms are altered.

Objective: To investigate the usefulness of PFD as an antifibrotic agent in clinical and experimental models of fibrotic disease.

Conclusions: There is a growing understanding of the molecular effects of PFD on the wound healing mechanism, leading to novel approaches for the management of fibrosis in lung, liver and renal tissues. Although the optimum treatment for fibrosis remains undefined, it is possible that combined therapeutic regimens that include this wide-application molecule, pirfenidone, could offer a useful treatment for fibrotic disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Chemical characteristics of the pirfenidone molecule.
Figure 2
Figure 2
Molecular mechanisms of pirfenidone in the reduction in fibrosis. Green indicates the mechanisms promoted by pirfenidone; red indicates the mechanisms that are inhibited by this drug.
See this image and copyright information in PMC

References

    1. ClinicalTrials.gov. http://clinicaltrials.gov/ct2/results?term=pirfenidone1
    1. Shi S, Wu J, Chen H, Chen H, Wu J, Zeng F. Single- and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy Chinese volunteers. J Clin Pharmacol. 2007;47:1268–1276. doi: 10.1177/0091270007304104. - DOI - PubMed
    1. Rubino CM, Bhavnani SM, Ambrose PG, Forrest A, Loutit JS. Effect of food and antiacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm Pharmacol Ther. 2009;22:279–285. doi: 10.1016/j.pupt.2009.03.003. - DOI - PubMed
    1. Cho ME, Kopp JB. Pirfenidone: an anti-fibrotic therapy for progressive kidney disease. Expert Opin Investig Drugs. 2010;19:275–283. doi: 10.1517/13543780903501539. - DOI - PMC - PubMed
    1. Braim AE, Macdonald MH, Bruss ML, Stanley SD, Giri JK, Giri SN. Pharmacokinetics and clinical effects of pirfenidone administered intravenously in horses. Am J Vet Res. 2008;69:952–960. doi: 10.2460/ajvr.69.7.952. - DOI - PubMed